Project Grant R44AG077984
Award Date 9/1/22
Completion Date 8/31/24
Dollars Obligated $2.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
- Summary This Cooperative Agreement, awarded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), funds UC San Diego to conduct in vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate the safety profile of GSM-779690, a small molecule G-secretase modulator (GSM) candidate therapeutic for Alzheimer's disease. The award totals $3,225,280 and runs from August 15, 2025, through July 31, 2027. The research aims to support...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
- Federal Grant Award Summary The National Institute on Aging awarded Brigham & Women's Hospital a $6.47 million Project Grant (R01) effective September 1, 2025 through August 31, 2030 under the Aging Research program (CFDA 93.866) to support the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and Alzheimer Plasma Extension (APEX) Study. The A3 Trial is a Phase IIB prevention study designed to test low-dose lecanemab, a monoclonal antibody that removes amyloid-beta, in cognitively...
- This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
- Federal Cooperative Agreement Award Summary Award Overview Artery Therapeutics, Inc. received a $2.64 million Cooperative Agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with an ultimate completion date of March 15, 2028. The awardee will conduct clinical research and development services for CS6253, an ABCA1 (ATP-binding-cassette-transporter A1) agonist therapeutic candidate targeting hereditary APOE4...
- Federal Grant Award Summary Oligomerix Inc. received a $999,758 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) on August 20, 2025, with a completion date of February 19, 2026. The award funds a 13-week Good Laboratory Practice (GLP) toxicity study of OLX-07010 in Beagle dogs followed by a 4-week recovery period. This preclinical study is designed to support the continued clinical development of OLX-07010, a small molecule drug candidate...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Advantage Therapeutics, Inc. a Project Grant of $1,249,957 (awarded September 20, 2025) under the Aging Research program (CFDA 93.866) to conduct preclinical and Investigational New Drug (IND)-enabling studies on a novel small-molecule disease-modifying therapeutic for Alzheimer's disease. The proposed treatment is designed to reduce brain inflammation and restore phagocytosis, thereby improving amyloid...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
- Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...
- Federal Grant Award Summary Epoch Biotech, LLC received a $498,709 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on August 20, 2025, with a completion date of August 19, 2026. The grant supports preclinical research to develop and validate the therapeutic efficacy of an apolipoprotein E (APOE) targeted humanized antibody (7C11) for Alzheimer's disease treatment. The research builds upon the discovery of a protective APOE3 variant (the...